Clinical Efficacy of Dapagliflozin in Patients With Ckd: Results of a Prospective Follow-Up

Goal. To evaluate the efficacy and safety of dapagliflozin in patients with chronic kidney disease (CKD) of various stages in routine clinical practice. Materials and methods. A prospective study conducted at the Republican Clinical Hospital in Makhachkala from November 2023 to April 2025 included 32 patients with stage 2-4 CKD. Participants were randomly assigned to dapagliflozin (10 mg/day) and placebo groups. The main endpoint was the time before a decrease in eGFR ≥50%, the development of terminal renal failure, or death from a renal/cardiovascular cause. Results. In the dapagliflozin group, there was a tendency to a lower incidence of primary and secondary adverse outcomes. The average annual decrease in eGFR in the dapagliflozin group was 2.0 ml/min/1.73 m2 compared with 3.1 ml/min/1.73 m2 in the placebo group (p=0.01). The frequency of side effects was comparable between the groups. Conclusions. Dapagliflozin has demonstrated a beneficial effect on the rate of decrease in renal function and the frequency of cardiorenal complications in CKD, confirming the possibility of its safe use even in patients with a marked decrease in eGFR.